Modification of gene expression induced by siRNA targeting of estrogen receptor α in MCF7 human breast cancer cells

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 231-242

  Luqmani, Yunus A ^a   Al Azmi, A ^a   Al Bader, M ^a   Abraham, G ^a   El Zawahri, M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor; Microarrays; PCR; SiRNA

Indexed keywords

CD68 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; DOUBLE STRANDED RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAMOXIFEN; VIMENTIN; ESR1 PROTEIN, HUMAN; MESSENGER RNA; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL FUNCTION; CELL GROWTH; CELL STRAIN MCF 7; CELL SYNCHRONIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIUM; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESOTHELIUM; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION; BREAST TUMOR; DNA MICROARRAY; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR MARKERS, BIOLOGICAL;

EID: 60749137227     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000145     Document Type: Article

References (65)

1. Jensen EV: The oestrogen receptor: a model for molecular medicine. Clin Cancer Res 9: 1980-1989, 2003.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt IS, Yakovlev AY, Habbema JD and Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784-1792, 2005.
3. Strasser-Weippl K and Goss E: Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 23: 1751-1759, 2005.
4. MacGregor JI and Jordan VC: Basic guide to the mechanisms of anti-estrogen action. Pharmacol Rev 50: 151-196, 1998.
5. Early Breast Cancer trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for ealr breast cancer on reccurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717, 2005.
6. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P: Overview of the main outcomes in breast cancer prevention trials. Lancet 361: 296-300, 2003.
7. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW and McDonnell DP: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context an dmediated by two functionally distinct intramolecular regions. Mol Endocrinol 8: 21-30, 1994.
8. McDonnel DP, Clemm DL, Hermann T, Goldman ME and Pike JW: Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol Endocrinol 9: 659-669, 1995.
9. Ariazi EA, Ariazi JL, Cordera F and Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6: 181-202, 2006.
10. Cranney A, tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B and Guyatt G: IV. Meta-analysis of Raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23: 524-528, 2002.
11. Sanchez R, Nguyen D, Rocha W, White JH and Mader S: Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24: 244-254, 2002.
12. Carlson RW: The history and mechanism of action of fulvestrant. Clin Breast Cancer 6 (Suppl. 1): S5-S8, 2005.
13. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer Statistics 2005. CA Cancer J Clin 55: 10-30, 2005.
14. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng ME, Masamura S, Yue W and Berstein L: Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 10: 111-130, 2003.
15. Nicholson RI, Staka C, Boyns F, Hutcheson IR and Gee JM: Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer; new opportunities for therapy. Endocr Relat Cancer 11: 623-641, 2004.
16. Ring A and Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658, 2004.
17. Normanno N, Di Maio M, De Maio E, De Luc A, De Matteis A, Giordano A and Perrone F: On behalf of the NCI-Naples Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12: 721-747, 2005.
18. Lewis JS and Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591: 247-263, 2005.
19. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S and Yue W: Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193: 29-42, 2002.
20. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME and Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal anti-estrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993.
21. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JMW and Nicholson RI: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure anti-estrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788, 2001.
22. Fan P, Wang J, Santen RJ and Yue W: Long-term treatment with tamoxifen facilitates translocation of estrogen receptor (alpha) out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:,1352-1360, 2007.
23. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osbome CK and Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2 and p38 mitogen activated protein kinase. J Clin Oncol 23: 2469-2476, 2005.
24. Sharma D, Saxena NK, Davidson NE and Vertino PM: Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive co-repressor complexes. Cancer Res 66: 6370-6378, 2006.
25. Garcia M, Derocq D, Freiss G and Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89: 11538-11542, 1992.
26. Van den Berg HW, Lynch M, Martin J, Nelson J, Dickson GR and Crockard AD: Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br J Cancer 59: 522-526, 1989.
27. Sommer A, Hoffmann J, Lichtner RB, Schneider MR and Parczyk K: Studies on the development of resistance to the pure ant estrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85: 33-47, 2003.
28. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH and Nephew KP: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the anti-estrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966, 2006.
29. Larsen SS, Madsen MW, Jensen BL and Lykkesfeldt AE: Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72: 1129-1136, 1997.
30. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA and Clarke R: MCF7/LCC9: an ant estrogen-resistant MCF-7 variant in which acquired resistance to the steroidal ant estrogen ICI 182,780 confers an early cross-resistance to the non-steroidal ant estrogen tamoxifen. Cancer Res 57: 3486-3493, 1997.
31. Nemere I, Pietras RJ and Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 88: 438-445, 2003.
32. Li L, Haynes MP and Bender JR: Plasma membrane localisation and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100: 4807-4812, 2003.
33. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P and Levin ER: Identification of a structural determinant necessary for the localization and function of estrogen receptor at the plasma membrane. Mol Cell Biol 23: 1633-1646, 2003.
34. Chung YL, Sheu ML, Yang SC, Lin CH and Yen SH: Resistance to tamoxifen induced apoptosis is associated with direct interaction between HER2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 97: 306-312, 2002.
35. Kahler S, Nuedling S, van Eickels M, Vetter H, Meyer R and Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275: 18447-18453, 2000.
36. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR and De Placido S: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741-4748, 2005.
37. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Know1den JM, McClelland RA, Jordan N, Wakeling AE and Nicholson RI: The anti-epidermal growth factor receptor agent gefitinib (ZD1839/h-essa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144: 5105-5117, 2003.
38. Elbashir SM, Harborth J, Lendeck BW, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
39. Pfaffl MW: A new mathematical model for relative quantitation in real-time RT-PCR. Nucleic Acids Res 29: E45-E50, 2001.
40. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
41. Sui G, Soohoo C, Affar B, Gay F, Shi Y, Forrester WC and Shi Y: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520, 2002.
42. Fu HJ, Jia LT, Bao W, Zhao J, Meng YL, Wang CJ, Yao LB, Chen SY and Yang AG: Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliteration and enhances apoptosis in breast cancer cells. Cancer Biol Ther 5: 842-847, 2006.
43. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP and Huang THM: Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64: 8184-8192, 2004.
44. Chan CM, Martin LA, Johnston SR, Ali S and Dowsett M: Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81: 333-341, 2002.
45. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C and Dowsett M: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J Biol Chem 278: 30458-30468, 2003.
46. Yue W, Wang JP, Conaway MR, Li Y and Santen RJ: Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 86: 265-274, 2003.
47. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S and Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89: 111-117, 2000.
48. Speirs V, Malone C, Walton DS, Kerin MJ and Atkin SL: Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59: 5421-5424, 1999.
49. Zhao C, Matthews J, Tujague M, Wan J, Ström A, Toresson G, Lam EW, Cheng G, Gustafsson JA and Dahlman-Wright K: Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67: 3955-3962, 2007.
50. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: Molecular cloning and characterization of human estrogen receptor-Cx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512, 1998.
51. Tang CK, Perez C, Grunt T, Waibel C, Cho C and Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350-3358, 1996.
52. Liu Y, el-Ashry D, Chen D, Ding IY and Kern FG: Emergence of MCF-7 cells over-expressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progressidn. Cell Growth Differ 5: 1263-1274, 1994.
53. Larsen SS, Egeblad M, Jäättelä M and Lykkesfeldt AE: Acquired anti-estrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58: 41-56, 1999.
54. De Cremoux P, Tran-Perennou C, Brockdorff BL, Boudou E, Brünner N, Magdelénat H and Lykkesfeldt AE: Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with anti-estrogens. Endocr Relat Cancer 10: 409-418, 2003.
55. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185: 191-203, 2007.
56. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
57. Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S and Gelmann EP: Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res 49: 4258-4263, 1989.
58. Gilles C, Newgreen D, Sato H and Thompson EW: Matrix metalloproteases and epithelial - to mesenchymal transition: implications for carcinoma metastasis. In: Rise and Fall of Epithelial Phenotype. Savagner P (ed). Landes Bioscience Publishers, Georgetown, pp297-315, 2004.
59. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW and Gelmann EP: Loss of epithelial markers and acquisition of vimentin expression in adriamycin-and vinblastine-resistant human breast cancer cell lines. Cancer Res 52: 5190-5197, 1992.
60. Curmi PA, Noguès C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R and Bièche I: Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82: 142-150, 2000.
61. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG and Shak S: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11: 8623-8631, 2005.
62. Hu LD, Zou HF, Zhan SX and Cao KM: EVL (Ena/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages. Oncol Rep 19: 1015-1020, 2008.
63. In X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, Mueller SC, Ojeifo J, Chen WS, Hay N and Pestell RG: Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 104: 7438-7443, 2007.
64. Jordan NJ, Gee JM, Barrow D, Wakeling AE and Nicholson RI: Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 87: 167-180, 2004.
65. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L and Linsley PS: Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187, 2006.